14 Results for "

anti-prostate

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "anti-prostate" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-N7043
CAS No.: 142796-21-2
Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity [1][2][3].
loading...
    loading...
Cat. No.: HY-136242
CAS No.: 2168525-92-4
Purity:  98.09%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Endocrinology Cancer

UT-34 is a potent, selective, orally bioactive second-generation pan-androgen receptor (AR) antagonist and degrader, with IC50 values of 211.7 nM, 262.4 nM, and 215.7 nM for wild-type AR, F876L-AR, and W741L-AR, respectively. UT-34 binds to the ligand-binding domain (LBD) and functional 1 (AF-1) domain of AR and requires the ubiquitin-proteasome pathway for AR degradation. UT-34 has anti-prostate cancer effects.
loading...
    loading...
Cat. No.: HY-N7645
CAS No.: 154-36-9
Synonyms: Trifoside; Prunetin 4′-O-β-D-glucopyranoside
Prunetrin (Trifoside) is a flavonoid identified as a potential anti-prostate cancer agent in in silico screening .
loading...
    loading...
Cat. No.: HY-145259
CAS No.: 3023019-99-7
Purity:  ≥98.0%
Research Areas:  

Cancer

HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC50s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC50=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-W748509
CAS No.: 88660-10-0
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .
loading...
    loading...
Cat. No.: HY-L124
3,655 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 3,655 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

Cat. No.: HY-163940
CAS No.: 2647877-84-5
Research Areas:  

Cancer

LX1 is an anti-prostate cancer compound that targets androgen receptor (AR), AR variants and steroidogenic enzyme AKR1C3. LX1 inhibits the enzymatic activity of AKR1C3, reduces the conversion of androstenedione to testosterone and reduces the expression of AR and AR-V7 and downregulates their target genes. LX1 overcomes the resistance of tumor cells to Enzalutamide (HY-70002), and the combination with Enzalutamide (HY-70002) further inhibits tumor growth .
loading...
    loading...
Cat. No.: HY-118375
CAS No.: 1072807-15-8
Synonyms: ISC-4
Target:  

Apoptosis

Research Areas:  

Cancer

Phenylbutyl isoselenocyanate (ISC-4) is a selective apoptosis inducer that increases reactive oxygen species levels to inhibit androgen receptor (AR) and activate p53 pathway. Phenylbutyl isoselenocyanate induces apoptosis in LNCaP prostate cancer cells and has anti-prostate cancer properties.
loading...
    loading...
Cat. No.: HY-155609
Target:  

VEGFR

Research Areas:  

Cancer

VEGFR-2-IN-31 (compound 3i) is a potent VEGFR-2 inhibitor (IC50=8.93 nM), and an anti-prostate cancer agent. VEGFR-2-IN-31 arrests cell cycle at the S-phase and induces apoptosis.
loading...
    loading...
Cat. No.: HY-155610
Target:  

VEGFR

Research Areas:  

Cancer

VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2 with an IC50 of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC50 of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research .
loading...
    loading...
Cat. No.: HY-N7043R
CAS No.: 142796-21-2
Isosilybin A (Standard) is the analytical standard of Isosilybin A (HY-N7043). Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity [1][2][3].
loading...
    loading...
Cat. No.: HY-N8230
CAS No.: 2231756-23-1
Ganosinensic acid C is a triterpenoid compound that can be extracted from Ganoderma lucidum. Ganosinensic acid C has important biological activities such as anti-tumor, anti-prostate cancer, anti-inflammatory, and inhibition of HIV-I protease. Ganosinensic acid C has an IC50 value of 10.5 μM against human highly metastatic lung cancer cell line 95D. Ganosinensic acid C has an IC50 value of Ganosinensic acid C against cervical cancer cell line Hela is 13.2 μM .
loading...
    loading...
Cat. No.: HY-180996
CAS No.: 667914-07-0
Research Areas:  

Cancer

VARS1-IN-2 (Compound 2901) is a VARS1 inhibitor with a Kd of 0.014 µM. VARS1-IN-2 does not alter VARS1 expression either at mRNA or protein level. VARS1-IN-2 exerts anti-prostate cancer effects mainly through interfering VARS1’s tRNA aminoacylation activity but not its expression .
loading...
    loading...
Cat. No.: HY-159739
CAS No.: 708291-86-5
Target:  

Androgen Receptor

Research Areas:  

Cancer

M17-B15 is an androgen receptor dimerization inhibitor with an IC50 of 30 nM. M17-B15 effectively disrupts AR self-association, thereby suppressing AR signaling. M17-B15 exhibits extraordinary anti- prostate cancer (PCa) efficacy in vitro and in mouse xenograft tumor models.M17-B15 can be used for the study of prostate cancer .
loading...
    loading...
  • 1